Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8870-8877. doi: 10.26355/eurrev_201910_19282.
MiR-1 has been reported to act as an inhibitory microRNA in gastric cancer (GC). This study aimed to investigate the regulatory mechanism by which miR-1-3p blocks the progression of GC by targeting stanniocalcin 2 (STC2).
The expression level of miR-1-3p in GC was assessed via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Expressions of STC2 were measured by qRT-PCR and Western blot analysis. Proliferation and invasion assays were detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assays, respectively. Moreover, the dual-luciferase reporter assay was used to confirm the binding sites between miR-1-3p and STC2.
MiR-1-3p was significantly down-regulated in GC. Moreover, abnormal expression of miR-1-3p was correlated with GC tumor size. Functionally, overexpression of miR-1-3p inhibited proliferation and invasion in GC by inhibiting stanniocalcin 2 (STC2) expressions. In contrast, STC2 was significantly up-regulated in GC. Furthermore, miR-1-3p negatively regulated STC2 expression in GC. The upregulation of STC2 weakened the inhibitory effect of miR-1-3p in GC.
MiR-1-3p suppressed cell proliferation and invasion by targeting STC2 in GC, providing a novel therapeutic target for GC.
已有研究报道 miR-1 在胃癌（GC）中作为一种抑制性 microRNA。本研究旨在探讨 miR-1-3p 通过靶向 STC2 阻断 GC 进展的调控机制。
通过实时定量聚合酶链反应（qRT-PCR）评估 GC 中 miR-1-3p 的表达水平。通过 qRT-PCR 和 Western blot 分析测量 STC2 的表达。通过 MTT（3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐）和 Transwell 分析分别检测增殖和侵袭试验。此外，双荧光素酶报告基因实验用于确认 miR-1-3p 和 STC2 之间的结合位点。
miR-1-3p 在 GC 中显著下调。此外，miR-1-3p 的异常表达与 GC 肿瘤大小相关。功能上，miR-1-3p 通过抑制 STC2 的表达抑制 GC 中的增殖和侵袭。相反，GC 中 STC2 显著上调。此外，miR-1-3p 负调控 GC 中的 STC2 表达。STC2 的上调削弱了 miR-1-3p 在 GC 中的抑制作用。
miR-1-3p 通过靶向 STC2 抑制 GC 中的细胞增殖和侵袭，为 GC 提供了一个新的治疗靶点。
